Kirk Chang
Cardiovascular Disease · Los Angeles, CANPI 1215924105
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 597 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations.
Across 597 payments — averaging $22.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Amgen$2K
- AstraZeneca$1K
- Edwards Lifesciences$885
- Amarin Pharma, Inc.$770
- Pfizer$699
- plus $7K from 43 others
What the payments were for
- Speaking & faculty fees$2001%
- Food & beverage$13,36299%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,562 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 94 | $88,866 |
| EntrestoSacubitril/Valsartan | 50 | $58,091 |
| OzempicSemaglutide | 48 | $45,817 |
| VascepaIcosapent Ethyl | 39 | $37,119 |
| EliquisApixaban | 29 | $34,659 |
| Praluent PenAlirocumab | 42 | $28,993 |
| XareltoRivaroxaban | 26 | $25,525 |
| FarxigaDapagliflozin Propanediol | 19 | $15,864 |
| LivaloPitavastatin Calcium | 29 | $13,250 |
| EdarbiAzilsartan Medoxomil | 19 | $12,800 |
| Droxidopa | 13 | $9,415 |
| BelsomraSuvorexant | 13 | $5,661 |
| Dexlansoprazole DrDexlansoprazole | 16 | $3,973 |
| BrilintaTicagrelor | 11 | $3,505 |
| Memantine Hcl ErMemantine Hcl | 24 | $2,484 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $1,920 | $58,09150 claims |
| Novo NordiskOzempic | $447 | $45,81748 claims |
| PfizerEliquis | $699 | $34,65929 claims |
| Johnson & JohnsonXarelto | $441 | $25,52526 claims |
| AstraZenecaFarxiga, Brilinta | $1,049 | $19,36930 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $23 | $13,25029 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $193 | $12,80019 claims |
| MerckBelsomra | $148 | $5,66113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Los Angeles
- Cathleen Bairey-MerzLos Angeles$1.2M
- Karol WatsonLos Angeles$553K
- Jamil AboulhosnLos Angeles$423K
- Darren BermanLos Angeles$392K
- Arash NayeriLos Angeles$281K
- Gregg FonarowLos Angeles$260K
- Martha GulatiLos Angeles$141K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.